Showing papers in "The Lancet Haematology in 2020"
1,152 citations
TL;DR: The findings show that endotheliopathy is present in COVID-19 and is likely to be associated with critical illness and death, and strategies to mitigate its progression might improve outcomes in CO VID-19.
779 citations
University of Insubria1, University of Pavia2, University of Eastern Piedmont3, University of Bologna4, University of Verona5, Humanitas University6, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico7, University of Milan8, University of Genoa9, University of Catania10, University of Parma11, University of Pisa12, University of Turin13, University of Perugia14, Sapienza University of Rome15, University of Padua16, University of Brescia17, University of Modena and Reggio Emilia18, University of Siena19, University of Udine20, Università Campus Bio-Medico21, Catholic University of the Sacred Heart22
TL;DR: This study adds to the evidence that patients with haematological malignancies have worse outcomes and the general Italian population with COVID-19 has high mortality, by calculating standardised mortality ratios between observed death in the study cohort and expected death by applying stratum-specific mortality rates.
408 citations
TL;DR: Wang et al. as mentioned in this paper explored the haematological characteristics and related risk factors in patients with COVID-19 and found that the onset of sepsis-induced coagulopathy was typically before overt disseminated intravascular coagulation.
344 citations
307 citations
Charité1, University of Helsinki2, Catholic University of the Sacred Heart3, Erasmus University Rotterdam4, University Hospitals Birmingham NHS Foundation Trust5, University of Graz6, University of Regensburg7, Boston Children's Hospital8, French Institute of Health and Medical Research9, Ankara University10, Sheba Medical Center11, University Hospital of Basel12, Katholieke Universiteit Leuven13, University of Valencia14, University Hospital Centre Zagreb15, University Medical Center Freiburg16, Medical University of Warsaw17
TL;DR: Key updates to these recommendations include a broader use of rabbit anti-T-cell globulin; lower steroid doses for the management of grade 2 acute GVHD with isolated skin or upper gastrointestinal tract manifestations; fluticasone, azithromycin, and montelukast should be used for bronchiolitis obliterans syndrome; and the addition of newer treatment options for resteroid-refractory acute and chronic GV HD.
236 citations
John Radcliffe Hospital1, University of Oxford2, NHS Blood and Transplant3, Imperial College London4, Haukeland University Hospital5, Norwegian Armed Forces6, University of Cambridge7, Héma-Québec8, Canadian Blood Services9, University of Toronto10, Mount Sinai Hospital11, University Health Network12, Erasmus University Rotterdam13, University of Manchester14
TL;DR: This work systematically searched for relevant studies addressing the transfusion chain—from donor, through collection and processing, to patients—to provide a synthesis of the published literature and guidance during times of potential or actual shortage.
199 citations
University of Liverpool1, Institut Jules Bordet2, University of Turin3, Hackensack University Medical Center4, Leiden University Medical Center5, St. Vincent's Health System6, VU University Amsterdam7, AIIMS, New Delhi8, Tel Aviv University9, Cleveland Clinic10, Medical University of Vienna11, Stony Brook University12, Paris Diderot University13, Ghent University14, National and Kapodistrian University of Athens15, Cliniques Universitaires Saint-Luc16, Hospital Universitario La Paz17
TL;DR: Single-drug oral selinexor induced durable responses and had a manageable adverse events profile in patients with relapsed or refractory DLBCL who received at least two lines of previous chemoimmunotherapy, and could be considered a new oral, non-cytotoxic treatment option in this setting.
184 citations
TL;DR: It is hypothesized that venetoclax with 10-day decitabine could have improved activity in patients with newly diagnosed AML and those with relapsed or refractory AML, particularly in high-risk subgroups, as well as safety, overall survival, and duration of response.
168 citations
TL;DR: The most frequently reported grade 3 and grade 4 treatment-related adverse events were increased γ-glutamyltransferase (seven [6%] of 127 patients) and increased alanine aminotransferase (four [3].
163 citations
Medical University of Vienna1, Bayer2, University of Cincinnati Academic Health Center3, Cincinnati Children's Hospital Medical Center4, Nationwide Children's Hospital5, Kazan State Medical University6, Riley Hospital for Children7, Paris Descartes University8, Boston Children's Hospital9, University Medical Center Groningen10, McMaster Children's Hospital11, Sheba Medical Center12, Charité13, University of Montpellier14, University of Padua15, Northwestern University16, Baylor College of Medicine17, Ural Federal University18, King's College London19, Newcastle upon Tyne Hospitals NHS Foundation Trust20, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico21, Nemours Foundation22, University of Alberta23, Children's Hospital Los Angeles24, McMaster University25, Maastricht University Medical Centre26, Royal Children's Hospital27, Katholieke Universiteit Leuven28
TL;DR: Treatment with rivaroxaban resulted in a similarly low recurrence risk and reduced thrombotic burden without increased bleeding, as compared with standard anticoagulants in children with acute venous thromboembolism.
University of Bologna1, Ankara University2, Sapienza University of Rome3, National and Kapodistrian University of Athens4, Erasmus University Rotterdam5, VU University Medical Center6, University of Turin7, University of Catania8, University of Udine9, University of Milan10, Charles University in Prague11, Radboud University Nijmegen12, University of Perugia13, Aarhus University Hospital14, Albert Schweitzer Hospital15, Maastricht University16, University of Ostrava17, Leiden University Medical Center18, Kantonsspital St. Gallen19, Norwegian University of Science and Technology20, University of Copenhagen21, Utrecht University22, Instituto Português de Oncologia Francisco Gentil23, Monash University24
TL;DR: Progressive progression-free survival was significantly improved with autologous HSCT compared with VMP and bortezomib-melphalan-prednisone (VMP) as intensification therapy, and bORTezomIB-lenalidomide-dexamethasone (VRD) consolidation therapy with no consolidation.
Spanish National Research Council1, Karolinska University Hospital2, Medical University of Lublin3, University of Silesia in Katowice4, Charles University in Prague5, First Faculty of Medicine, Charles University in Prague6, University of Calgary7, University of Barcelona8, Institute of Cancer Research9, The Royal Marsden NHS Foundation Trust10, Nagoya City University11, Harvard University12, Sheba Medical Center13, University of Bologna14, University of Bordeaux15, Queen Elizabeth II Health Sciences Centre16, Catholic University of the Sacred Heart17, Janssen Pharmaceutica18, Princeton University19
TL;DR: Overall response and Ctrough met the predefined non-inferiority criteria and the most common grade 3 and 4 adverse events were anaemia and anaemia.
TL;DR: The safety and feasibility of single UM171-expanded cord blood transplantation in patients with haematological malignancies who do not have a suitable HLA-matched donor was investigated and the primary endpoints were feasibility of UM171 expansion, safety of the transplant, and kinetics of hematopoietic reconstitution.
St James's University Hospital1, Royal Bournemouth Hospital2, University of Plymouth3, University College London4, University of Texas MD Anderson Cancer Center5, University of Southampton6, University of Amsterdam7, University of Bologna8, The Royal Marsden NHS Foundation Trust9, Churchill Hospital10, University Medical Center Utrecht11, National and Kapodistrian University of Athens12, Georgetown University13, University of Leicester14, NewYork–Presbyterian Hospital15
TL;DR: This study provides evidence that acalabrutinib is active as single-agent therapy with a manageable safety profile in patients with treatment-naive, or relapse or refractory Waldenström macroglobulinemia.
TL;DR: The authors showed that endothelial cells play a key role in orchestrating the unusual pulmonary intravascular coagulopathy associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
TL;DR: This study showed that additional ultrasound-accelerated catheter-directed thrombolysis does not change the risk of post-thrombotic syndrome 1 year after acute iliofemoral deep-vein thrombosis compared with standard therapy alone.
Harvard University1, Stanford University2, University of Ulm3, National and Kapodistrian University of Athens4, University College London Hospitals NHS Foundation Trust5, University of Amsterdam6, University of Paris7, Utrecht University8, St James's University Hospital9, Memorial Sloan Kettering Cancer Center10, Australian National University11, University of Sydney12
TL;DR: An international consensus panel was formed to update treatment recommendations for Waldenström macroglobulinaemia and alkylating drugs and proteasome inhibitors and BTK inhibitors alone or in combination with rituximab are preferred first-line therapy options for symptomatic patients.
TL;DR: A systematic review and meta-analysis of published and unpublished clinical trials that reported data on the outcomes of adult or paediatric patients that were treated with anti-CD19 CAR T cells for relapsed or refractory B-cell acute lymphocytic leukaemia aimed to systematically analyse the outcomes.
University of Paris1, Osaka City University2, University of Naples Federico II3, Semmelweis University4, Guy's and St Thomas' NHS Foundation Trust5, University of Texas Health Science Center at San Antonio6, Ospedale di Circolo e Fondazione Macchi7, Royal Brisbane and Women's Hospital8, Ruhr University Bochum9, University of Yamanashi10, Autonomous University of Barcelona11, University of Pavia12, Charité13, Novartis14, University of Florence15, University of Texas MD Anderson Cancer Center16
TL;DR: This study aimed to compare the long-term safety and efficacy of ruxolitinib with best available therapy in patients with polycythaemia vera who were resistant to or intolerant of hydroxyurea and assessed the durability of primary composite response, complete haematological remission, Overall survival, patient-reported outcomes, and safety after 5-years of follow-up.
University of Duisburg-Essen1, University of Münster2, Semmelweis University3, University of Mainz4, Heidelberg University5, Dresden University of Technology6, University of Rostock7, Karolinska University Hospital8, University of Milan9, University of Brescia10, University of Regensburg11, University of Göttingen12, Gdańsk Medical University13, Technische Universität München14, Sapienza University of Rome15, Medical University of Silesia16, Rzeszów University17
TL;DR: Treosulfan was non-inferior to busulfan when used in combination with fludarabine as a conditioning regimen for allogeneic HSCT and safety in all patients who received treatment was assessed.
Nottingham University Hospitals NHS Trust1, University of Modena and Reggio Emilia2, Sungkyunkwan University3, Samsung Medical Center4, University of Chile5, University of Washington Medical Center6, Memorial Sloan Kettering Cancer Center7, University of St. Gallen8, Barts Health NHS Trust9, Tel Aviv University10, State University of Campinas11, Hospital Maciel12, Columbia University13
TL;DR: A clinically significant improvement in the survival of patients with ENkTL treated in routine clinical practice over the past decade is described, likely to be attributable to the increasing use of treatment protocols specific for ENKTL.
New York University1, Harvard University2, Johns Hopkins University3, Emory University4, Indiana University5, Rutgers University6, Stanford University7, Medical College of Wisconsin8, Fox Chase Cancer Center9, University of Pennsylvania10, Thomas Jefferson University11, Vanderbilt University12, Northwestern University13, National Institutes of Health14, Washington University in St. Louis15, Mayo Clinic16
TL;DR: The safety and activity of combinations of brentuximab vedotin with nivolumab or ipilimumab, or both in patients with relapsed or refractory Hodgkin lymphoma was evaluated to determine the maximum tolerated dose and dose limiting toxicities.
Cornell University1, Memorial Sloan Kettering Cancer Center2, Harvard University3, University of Texas MD Anderson Cancer Center4, University of Colorado Denver5, NewYork–Presbyterian Hospital6, University of Texas Southwestern Medical Center7, Cleveland Clinic8, Agios Pharmaceuticals9, Celgene10, Institut Gustave Roussy11, Université Paris-Saclay12
TL;DR: The clinical outcomes of enasidenib monotherapy in a subgroup of patients with myelodysplastic syndromes harbouring mutations in IDH2 from the AG221-C-001 trial were established and overall response rate, duration of response, and overall and event-free survival analyses were by intention-to-treat.
TL;DR: In this analysis, daratumumab 16 mg/kg monotherapy showed durable responses and there were no new safety concerns with longer follow-up of these two studies.
TL;DR: A phase 1-2 study of melflufen and dexamethasone in patients with relapsed and refractory multiple myeloma to determine the maximum tolerated dose and to investigate its safety and efficacy is completed.
TL;DR: This narrative Review describes important concepts in machine learning for unfamiliar readers, details machine learning's current applications in haematological malignancy, and summarises important concepts for clinicians to be aware of when appraising research that uses machine learning.